Evidence map›Paper›PMID 36546757›Full record

ArticleNucleic acids research2023

Optimized high-throughput screening of non-coding variants identified from genome-wide association studies.

Tunc Morova, Yi Ding, Chia-Chi F Huang, Funda Sar, Tommer Schwarz, Claudia Giambartolomei, Sylvan C Baca, Dennis Grishin, Faraz Hach, Alexander Gusev and 3 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic Variations in the Fibronectin 1 Gene (International journal of molecular sciences · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Tunc MorovaVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.ORCID 0000-0002-4062-6185
Yi DingBioinformatics Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-3595-2493
Chia-Chi F HuangVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Funda SarVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Tommer SchwarzBioinformatics Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-1777-3280
Claudia GiambartolomeiCentral RNA Lab, Istituto Italiano di Tecnologia, Genova 16163, Italy.ORCID 0000-0003-2786-1225
Sylvan C BacaDepartment of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Dennis GrishinDepartment of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Faraz HachVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.ORCID 0000-0003-1143-0172
Alexander GusevDepartment of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-7980-4620
Matthew L FreedmanDepartment of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Bogdan PasaniucBioinformatics Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-0227-2056
Nathan A LackVancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.ORCID 0000-0001-7399-5844
University of California, Los Angeles · USDana-Farber Cancer Institute · USHarvard University · USKoç University · TRUniversity of British Columbia · CA

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

The vast majority of disease-associated single nucleotide polymorphisms (SNP) identified from genome-wide association studies (GWAS) are localized in non-coding regions. A significant fraction of these variants impact transcription factors binding to enhancer elements and alter gene expression. To functionally interrogate the activity of such variants we developed snpSTARRseq, a high-throughput experimental method that can interrogate the functional impact of hundreds to thousands of non-coding variants on enhancer activity. snpSTARRseq dramatically improves signal-to-noise by utilizing a novel sequencing and bioinformatic approach that increases both insert size and the number of variants tested per loci. Using this strategy, we interrogated known prostate cancer (PCa) risk-associated loci and demonstrated that 35% of them harbor SNPs that significantly altered enhancer activity. Combining these results with chromosomal looping data we could identify interacting genes and provide a mechanism of action for 20 PCa GWAS risk regions. When benchmarked to orthogonal methods, snpSTARRseq showed a strong correlation with in vivo experimental allelic-imbalance studies whereas there was no correlation with predictive in silico approaches. Overall, snpSTARRseq provides an integrated experimental and computational framework to functionally test non-coding genetic variants.

Indexed as

Genome-Wide Association StudyRegulatory Sequences, Nucleic AcidGenetic Predisposition to DiseaseHumansMalePolymorphism, Single NucleotideTranscription FactorsTranscription Factors

Identifiers

PMID36546757
PMCPMC9943666
OpenAlexW4312095046

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.